Radiopharm Theranostics Ltd. announced interim results from its U.S. Phase 2b clinical imaging trial of RAD 101 in patients with brain metastases. According to the company, 92% of evaluable patients (11 out of 12) achieved concordance with MRI imaging, meeting the primary endpoint of the study. RAD 101, a novel small-molecule imaging agent targeting fatty acid synthase (FASN) and radiolabelled with Fluorine-18, demonstrated significant and selective tumor uptake in suspected or recurrent brain metastases. The interim data have been presented by the company, and a webinar is scheduled to discuss the findings. Radiopharm Theranostics also indicated plans to initiate a pivotal study by the end of 2026.